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Abstract: Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been described as positively
associated with cognitive functioning. Current meta-analyses have identified eicosapentaenoic acid
(EPA) as potentially more effective than docosahexaenoic acid (DHA). An especially vulnerable
subgroup that might benefit from these beneficial effects are depressed youths. In this study,
we examined associations between red blood cell (RBC) DHA and EPA levels and depression severity
and verbal memory performance in a sample of 107 moderately (n= 63) and severely (n= 44) depressed
youths. The findings showed that youths with high RBC EPA levels had steeper learning curves
compared to those with moderate or low RBC EPA levels (Pillai’s Trace = 0.195, p = 0.027, ηp2 = 0.097).
No associations between RBC DHA levels or depression severity and verbal memory performance
were observed. Our results further confirm previous findings indicating a more important role of EPA
compared to DHA in relation to cognitive functioning. Future research should further investigate the
differential role of EPA and DHA concerning cognitive functioning in depressed youths. Evidence
supporting beneficial supplementation effects could potentially establish a recommendation for a
natural and easily accessible intervention for cognitive improvement or remission.
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1. Introduction
According to the World Health Organization (WHO), approximately 4.4% of the world’s population
suffer from depression [1], with a lifetime prevalence rate of approximately 10%–15% [2,3]. Although
the median age of onset lies at around 25 [2], the first symptoms and onset of depression often occur
as early as during childhood or adolescence [4], and earlier onset is associated with poorer health
outcomes, such as more depressive episodes, more suicide attempts, and poorer functional outcomes [5].
For adolescents, the one-year prevalence rates are estimated to lie around 5% with a large range of
approximately 0.2%–17% [6–9]. Depression is a very severe mental disorder and can lead to suicide,
which, in 2015, was the second leading cause of death amongst 15–29-year-olds. In youths, depression
has been deemed the leading cause of disability-adjusted life years (DALYs) and years lived with
disability (YLD) [10]. Altogether, these findings highlight the burden that this disease poses on today’s
youth and the devastating associated consequences.
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [11] defines
the diagnostic criteria for major depressive disorder (MDD), which include depressed mood, fatigue,
and diminished pleasure, as well as cognitive problems such as difficulties concentrating. To meet
the diagnostic criteria for MDD, at least five symptoms must have been present for most of the time
during the same two-week period. Symptoms must include either depressed mood or loss of interest
or pleasure. In children and adolescents, key symptoms also include irritable mood.
Clinical research to date has primarily focused on the emotional symptoms of depression, while
problems with cognition can equally impact everyday functioning and subjective quality of life [12–14].
Moreover, cognitive deficits have been associated with poorer antidepressant treatment outcome [15,16].
Cognitive impairments could be especially problematic when children and adolescents are affected.
At this critical stage in life, problems with concentration and cognition could lead to long-lasting
consequences concerning personal life and educational attainment [17,18]. Meta-analyses investigating
cognitive deficits in depressed adults have reported moderate impairments in several cognitive domains
compared to healthy controls [19–25]. Evidence from several studies suggests that these cognitive
problems remain at least partially present even in the remitted stage [26–28]. Although cognitive
complaints are equally part of the diagnostic criteria in youths, evidence for impaired cognitive test
performance in this subgroup of depressed individuals seems much more heterogeneous. Some
meta-analyses have found similar deficits to analyses with adult patients [29–31]. A qualitative review
by Vilgis et al. [32], however, concluded that while some studies reported cognitive deficits in depressed
children and adolescents, the majority did not find any impairments. Günther et al. [33] reported
heterogenous results with undisturbed attention, whereas memory impairment was associated with
depressive disorders.
In their review, McDermott and Ebmeier [34] reported negative associations between depression
severity and cognitive functioning in adults; however, this effect seemed domain-specific. In youths,
thus far only tendencies toward a similar association have been reported [35], highlighting the need
for further investigation into this subject. In the past few years, cognitive remission has become
an important goal for MDD treatment; however, treatment options concerning cognitive symptoms
are scarce. Evidence of positive cognitive effects of antidepressant medication has proven rather
heterogeneous [36–43].
Since the industrial revolution, nutritional patterns in Western societies have shifted toward foods
containing more omega-6 (n-6) compared to omega-3 (n-3) polyunsaturated fatty acids (PUFAs) [44].
These changes have been held responsible for the rise in different civilization diseases such as
cardiovascular diseases, but also in psychiatric diseases such as depression [45]. n-3 PUFA deficiency
Nutrients 2020, 12, 3630 3 of 25
has been associated with depression [46–48] and eicosapentaenoic acid (EPA) status has been negatively
associated with depression severity [49]. Meta-analytic evidence has further suggested beneficial
effects of n-3 PUFA supplementation on depression symptoms [50–54], especially with high doses of
EPA [50,51]. Interestingly, symptom severity might moderate this beneficial effect, as some studies
have reported stronger effects in more severely depressed patients [55]. However, other meta-analyses
in both adults [56] and children and adolescents [57] have revealed no beneficial effect of n-3 PUFAs
for the treatment of depressive disorder. In youths, however, only four randomized controlled trials
(RCTs) thus far have been included [57]. The anti-inflammatory properties of n-3 PUFAs have mostly
been made responsible for their beneficial effects in relation to depression [58]. Proinflammatory
cytokines have been shown to play a role in depression [59], and hence n-3 PUFAs have been discussed
to counteract these inflammatory processes [60].
n-3 PUFAs are vital for normal brain development [60–63]. Consequently, the past few years have
seen a renewed interest in the investigation of n-3 PUFAs in relation to cognition. Several studies in
youths have reported positive associations between reported dietary n-3 PUFA intake and cognitive
performance [64,65]. In a study by Montgomery et al. [66], low blood n-3 PUFA status was associated
with poorer reading abilities and working memory performance in children. Similarly, Wurff et
al. [67] reported better performance on an attention task for adolescents with higher n-3 PUFA status.
Meta-analyses of n-3 PUFA supplementation have reported mixed results, depending on the study
population investigated [68–75]. It remains unclear whether the specific type of n-3 PUFA ingested
might have significantly contributed to these heterogenous study results, as some meta-analyses have
suggested beneficial effects of EPA rather than docosahexaenoic acid (DHA) [68,76].
The question remains as to how n-3 PUFAs might affect cognition in depressed individuals, as
supplementation studies in depressed populations are very scarce [77]. The results reported by Rogers
et al. [78] showed no benefit of n-3 PUFA supplementation on cognition in adult individuals with
mild to moderate depression. In youths, however, Vesco et al. [79] reported decreased parent-rated
impairments in executive functioning after 12-week supplementation with n-3 PUFAs. To the best of
our knowledge, there is as yet no study investigating the associations between EPA and DHA statuses
and cognitive performance in depressed children and adolescents.
The aim of the current study was to address the previously mentioned research deficits and to
investigate verbal memory performance in depressed children and adolescents in relation to EPA and
DHA statuses as well as depression severity. The aforementioned research findings suggest that (1) EPA
but not DHA is positively associated with cognitive functioning, (2) depression severity is negatively
associated with cognitive functioning, and (3) depression severity might moderate the association
between EPA and depression symptoms. We hence hypothesized that patients with a high EPA status
would outperform patients with a low EPA status in verbal memory tasks and that this would be
especially evident in severely depressed compared to moderately depressed individuals. Furthermore,
we hypothesized that moderately depressed patients would outperform severely depressed patients.
If EPA but not DHA were to be identified as being associated with cognitive functioning in
depressed children and adolescents, this would prove important, especially for this specific population,
as EPA compared to DHA has also been considered to be more effective in the treatment of depression
symptoms [50,51]. Consequently, future RCTs could investigate EPA supplementation as an intervention
in these individuals, targeting both emotional and cognitive symptoms at the same time.
2. Materials and Methods
The findings reported in this present study were generated from data collected by the “The
Omega-3-pMDD trial,” a multi-center placebo-controlled trial aiming to investigate the efficacy of
omega-3 fatty acid supplementation in moderately to severely depressed children and adolescents aged
8–17 years. Two hundred and twenty patients across Switzerland will be recruited in order to investigate
both the psychopathological and cognitive effects of nine months of n-3 PUFA supplementation. In the
present study, we report cross-sectional findings from data collected prior to randomization to a
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treatment arm, with the exception of intellectual ability that was assessed six weeks post-randomization.
Funding was received from the Swiss National Foundation and the private foundations that are listed
later in the funding section. No industry funding was received. The clinical trial was registered on
www.ClinicalTrials.gov, protocol no. NCT03167307. The clinical trial’s design paper has already
been published [80]. The study was approved by the local ethics committee and was conducted
in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and later
amendments. All parents (or legal guardians) provided written informed consent and written or oral
assent was obtained from the participating children before entering the study.
2.1. Participants
Participants were recruited from seven different in- and outpatient services across Switzerland.
For inclusion, the patients had to meet the diagnostic criteria for MDD according to the Diagnostic
and Statistical Manual of Mental Disorders (DSM)-IV [81] and had to have reported symptoms of at
least moderate severity defined by a Children’s Depression Rating Scale [82] total score of ≥40 [83].
Patients who met the DSM-IV diagnostic criteria for an eating disorder within the last six months or
the diagnostic criteria for a lifetime diagnosis of schizophrenia, bipolar affective disorder, or substance
dependency were excluded from the trial. Mental retardation, pervasive development disorder,
or pre-existing neurological or medical conditions that are likely to be responsible for depression
symptoms constituted further exclusion criteria. Antidepressant treatment was allowed at study entry
to avoid selection bias toward less severely depressed patients. Lastly, patients regularly supplementing
n-3 PUFAs within the last six months (dosage limit set at 600 mg/day) or patients unable to follow the
study procedures (e.g., due to a language barrier) were also excluded.
During the screening visit, the inclusion and exclusion criteria were assessed using the Kiddie
Schedule for Affective Disorders and Schizophrenia (K-SADS-PL) [84] and the Children’s Depression
Rating Scale revised (CDRS-R) [82]. Patients meeting all inclusion and no exclusion criteria were then
included in the lead-in phase of the trial (7–14 days). During the lead-in phase, all participants received
a placebo in a single blinded fashion and psychopathological, cognitive, and bloodwork baseline data
were collected. Assessment of the inclusion and exclusion criteria was repeated at the end of this
phase, after which patients were randomized to a treatment arm in a double-blind fashion. At the
time of analysis, the sample consisted of 107 patients that met all of the inclusion and no exclusion
criteria at screening and had analyzed PUFA blood sample data. The current article investigated this
subsample in a cross-sectional manner using single cognitive and psychopathological assessments
from the lead-in phase of the trial.
2.2. Instruments
2.2.1. Sociodemographic Variables
Sociodemographic information and information on treatment history were obtained using the
patients’ medical records, as well as patient and parent interviews. Information on the course of
illness was collected via patients’ self-reports and parents’ reports. The patients’ medical records were
consulted for confirmation of these reports. Patients or parents provided further information where
information was missing or incomplete.
2.2.2. Independent Variables
Severity of Depression (CDRS-R)
The CDRS-R is a semi-structured clinical interview assessing the severity of depression using
17 depression symptoms [82]. Patients and parents provide information on 14 of these symptoms which
are then rated on a 7- or 5-point Likert scale, depending on the specific symptom. The interviewer
then integrates this information and provides a final score for each symptom. Three further nonverbal
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symptoms are rated by the interviewer only (depressed facial affect, hypoactivity and listless speech).
The final scores for each reported symptom, as well as the ratings on nonverbal symptoms are added
up to obtain a final score for depression severity. Scores of 30–39 can be interpreted as mild, 40–59
as moderate, and ≥60 as severe symptoms of depression [83]. Validation studies on CDRS-R have
reported good validity and reliability for depressed children and adolescents [85].
EPA and DHA Statuses
Venous blood samples were collected. For determination of erythrocyte fatty acid composition,
blood was drawn into EDTA tubes, centrifuged, and then the plasma and buffy coat taken off; the
erythrocytes were then frozen at −80 ◦C until analysis. The fatty acid composition of the erythrocytes
was analyzed by gas chromatography at Omegametrix GmbH using previously described methods [86].
EPA and DHA statuses are given as a percentage of total fatty acids measured in RBCs.
2.2.3. Outcome Variables
Cognitive Tests—Memory
• Verbal Memory: VLMT We used a validated German version (Verbaler Lern- und
Merkfähigkeitstest (VLMT) [87]) of the Auditory Verbal Learning Test (AVLT) [88], in which a
list of 15 semantically independent words is presented auditorily to an individual and he or she
is asked to remember and reproduce as many words as possible. This process is repeated five
times. Then, a second list of 15 words (= interference list (I)) is presented and the individual is
asked to remember and reproduce as many words as possible from the second list. In the next
step, the individual is asked to reproduce the words from the first list. After 20–30 min, he or she
is once again asked to reproduce the first list of words. In the last step, the individual is asked to
recognize the words from a list of 50 semantically or phonetically related and unrelated words.
The test measures declarative verbal memory capacity. Short-term verbal memory is characterized
by the number of words correctly reproduced by the individual in each of the five rounds (T1, T2,
T3, T4, and T5). The long-term memory parameters are T7, which is the number of words from
the first list recalled after 20–30 min, and T5–T7, which is the difference between the number of
words recalled at T5 and T7. The interference score is I, which represents the number of correctly
reproduced words from the interference list, T6, which is the number of words from the first
list recalled after interference, and T5–6, which is the difference between the number of words
reproduced from the first list before and after interference. Lastly, recognition (W) is the number
of words correctly identified as belonging to the first list, and W–F is the correctly identified words
minus the words wrongly attributed to the first list.
• Numeric Memory: WISC-IV Digit Span The digit span subtest from the Wechsler Intelligence
Scale for Children—Fourth Edition (WISC-IV) [89] consists of two parts, namely, forward and
backward. In the first part, the individual has to reproduce sequences of digits of increasing
length. In the second part, the individual is instructed to repeat a sequence of digits in reverse
order. The test measures numeric short-term memory and working memory.
2.2.4. Control Variables
IQ: Reynolds Intellectual Assessment Scales and Screening (RIAS)
The RIAS is an intelligence test for individuals between 3 and 99 years of age, mostly used for
research purposes [90]. It includes two subtests, the results of which are added to form a verbal
intelligence index (VIX) and two subtests to form the nonverbal intelligence index (NIX). These are
then integrated into the global intelligence index (GIX). Reliability of the RIAS is high (Cronbach
α = 0.95 for the global index) [91,92].
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C-Reactive Protein (CRP)
High-sensitive CRP was measured in the plasma in an accredited medical laboratory using a
commercial assay with a coefficient of variation of 1.3% at 3.6 mg/L, to be used as a marker for low-grade
inflammation and as a stratification parameter for randomization. Values above 10 were excluded
from analysis, as they could have indicated infection.
Body Mass Index (BMI)
The BMI was calculated using weight (kg)/height (cm)2. BMI was not obtained in some cases
because of missing measurement tools and devices.
2.3. Statistical Analysis
Statistical Package for the Social Sciences (SPSS) software version 26 was used for all statistical
analyses. Descriptive statistics are given in order to describe the study sample characteristics.
Moderately and severely depressed patient groups were distinguished using a clinical cut-off of
the CDRS-R total score (40–59 = moderate; ≥60 = severe) [83]. Three approximately equally sized
groups were formed according to the data distribution of EPA and DHA statuses, because the patients’
n-3 PUFA statuses were all low when referring to the currently proposed ideal levels [93]. Hence,
the formation of three groups would allow for the investigation of especially low status and rather
normal values. Differences between moderately and severely depressed patients and differences
between EPA and DHA status groups for the investigation of potential confounding variables were
analyzed using chi-square tests, independent t-tests, and one-way ANOVAs, depending on the scale
level of the variable investigated. Non-parametric Mann–Whitney U or Kruskal–Wallis tests were only
used for strongly skewed data (>1, <(−1)), as in large sample sizes parametric tests should be robust
against the violation of normality assumption [94].
In order to investigate differences in memory scores depending on depression severity (moderate
vs. severe) and EPA and DHA statuses (low, intermediate, and high), multivariate analyses of covariance
(MANCOVAs) were computed to evaluate the VLMT short-term, long-term, and interference parameters
separately. Multivariate outliers were checked using Mahalanobis’ distances. Bonferroni correction
was applied for the interpretation of between-subjects effects and pairwise comparisons. For digit span
parameters, univariate analyses of covariance (ANCOVAs) were used for the forward and backward
parameters separately.
Conservative results using Pillai’s Trace instead of Wilk’s Lambda are reported [95]. Pillai’s Trace
values range from 0 to 1 with increasing values indicating a stronger contribution of the independent
variable to the model. For all MANCOVAs, normal distribution within groups was investigated using
Shapiro–Wilk tests and Q-Q plots where n ≤ 25. Box’s tests were used to evaluate the homogeneity
of variance–covariance matrices. Levene’s tests were used to assess the equality of error variances,
although the results should be robust against violation if none of the standard deviations are more
than four times as large as the corresponding smallest standard deviation [96]. The homogeneity of the
regression slopes was assessed for all covariates. Significance levels were set at p < 0.05.
3. Results
At the time of analysis, the subsample of patients that met all inclusion and no exclusion criteria
and where blood samples were available consisted of 107 patients. For one patient, the WISC digit
span scores were missing due to the fact that the test had not been done with this individual. RIAS
scores for seven patients were missing, because IQ testing was done six weeks post-randomization and
these patients had not yet reached week six of the study.
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3.1. Descriptive Statistics
Patients achieved average mean normative scores for both the VLMT total learning parameter
(
∑
T-15) (T-score, M = 49.15, SD = 9.21), as well as the WISC digit span score (scaled score metric,
M = 9.57, SD = 2.43). However, a significant proportion of patients achieved below average scores,
with 24 patients (22.42%) with T-scores < 40 for the VLMT; moreover, 24 patients (22.64%) achieved
scaled metric scores <8 for the digit span test. There was one outlier for the long-term memory
scores, with a Mahalanobis’ distance of 25.72 (critical value = 13.82); however, it was decided not to
exclude this participant because all other memory parameters were within normal range. Only 5.8%
achieved recognition normative scores below average and 67% recognized all 15 words from the list.
The skewness of the recognition data was −2.32 (SE = 0.23) and kurtosis was 6.51 (SE = 0.47). A total of
46.2% of the participants reached maximum recognition scores even when subtracting interference or
false positive mistakes (skewness of −1.691 (SE = 0.25) and kurtosis of 2.96 (SE = 0.47)). Hence, it was
decided to investigate depression severity and EPA/DHA group differences concerning recognition
scores using nonparametric Kruskal–Wallis and Mann–Whitney U tests instead of MANCOVAs.
Severity group formation resulted in a group of 63 moderately depressed patients and a group
of 44 severely depressed patients. The sociodemographic information, IQ, physiological parameters,
and psychopathology data are summarized in Table 1 for both severity groups. Severely depressed
patients were over proportionally female compared to moderately depressed patients; hence, gender
was later entered as a covariate for the ANCOVA and MANCOVA analyses. No other group differences
except CDRS-R score differences presented between severity groups. Importantly, no differences
concerning antidepressant use were found.
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Age 107 15.50(1.89) 8.67 18.00 15.25 (2.09) 15.85 (1.51) −1.630 0.106
Sex: %female 107 67% 57% 82% 7.166 0.007 **
Physiological
parameters
BMI 99 22.35(4.87) 14.00 39.80 21.86 (4.35) 23.06 (5.52) 1285.0 0.454
CRP 105 0.79 (1.26) 0 6.6 0.65 (0.81) 0.99 (1.69) 1220.0 0.410
IQ
RIAS VIX 100 101.73(9.93) 79 129 102.58 (10.18) 100.51(9.61) 1.019 0.102
NIX 100 106.33(8.93) 70 123 107.71 (8.61) 104.34 (9.12) 1.879 0.310
GIX 100 104.52(9.35) 76 128 105.78 (9.32) 102.68 (9.21) 1.651 0.102
Depression severity
CDRS-R Total score 107 57.73(7.76) 42 79 52.37 (4.18) 65.41 (4.54) −15.331 <0.001 ***
Severe % a 44 41.1% - - - -
Course of illness
Mean duration of
depression (months) Months 104
14.71
(11.69) 1 84 13.45 (9.76) 16.43 (13.84) 1503.0 0.228
Total number of
episodes 105 1.46 (0.95) 1 8 1.44 (1.10) 1.48 (0.70) 1490.0 0.230




Yes 102 37% 35% 40% 0.317 0.573
Note: ** p < 0.01, *** p < 0.001. CRP, C-reactive protein; BMI, body mass index; VIX, verbal intelligence index; NIX, nonverbal intelligence index; GIX, global intelligence index; RIAS,
Reynolds Intellectual Assessment Scales and Screening; CDRS-R, Children’s Depression Rating Scale revised. a CDRS-R severity scores: 40–59 =moderate, ≥60 = severe.
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EPA group formation resulted in three groups (n1 = 34, n2 = 39, and n3 = 34) with group means of
M1 = 0.34 (SD = 0.05), M2 = 0.46 (SD = 0.04), M3 = 0.66 (SD = 0.11). No gender (χ2 = 0.172, p = 0.918),
age (F(2,104) = 0.816, p = 0.445), IQ (F(2,97) = 2.317, p = 0.104), BMI (H(2) = 2.950, p = 0.229), CRP
(H(2) = 2.771, p = 0.250) differences or differences concerning antidepressant use (χ2 = 0.866, p = 0.649)
presented between the three groups. DHA group formation resulted in three groups (n1 = 36, n2 = 35,
and n3 = 36) with group means of M1 = 2.89 (SD= 0.22), M2 = 3.48 (SD= 0.20), and M3 = 4.54 (SD= 0.61).
Moreover, between these groups, no gender (χ2 = 0.468, p = 0.791), age (F(2,104) = 0.774, p = 0.464),
IQ (F(2,97) = 0.924, p = 0.401), (H(2) = 0.987, p = 0.611), CRP (H(2)= 0.539, p = 0.764) differences or
differences concerning antidepressant use (χ2 = 0.527, p = 0.768) were found.
As shown in Table 2, severely depressed patients had higher DHA and total omega-3 status
compared to moderately depressed patients. No significant differences concerning EPA status
were observed.
Table 2. Fatty acid status for moderately and severely depressed patients.
Total
Moderate




Fatty acid M (SD) M (SD) M (SD)
EPA 0.49 (0.15) 0.47 (0.14) 0.51 (0.16) −1.515 0.133
DHA 3.63 (0.79) 3.50 (0.71) 3.82 (0.87) −2.077 0.040 *
All n-6 34.37 (1.32) 34.45 (1.26) 34.32 (1.40) 0.512 0.609
All n-3 6.45 (1.0) 6.26 (0.93) 6.71 (1.06) −2.318 0.022 *
AA/EPA 35.10 (11.27) 36.08 (11.21) 33.74 (11.60) 1.045 0.298
Note: * p < 0.05. EPA, eicosapentaenoic acid; DHA, docosahexaenoic; n-6, omega-6; n-3, omega-3; AA,
arachidonic acid.
3.2. Main Analysis—EPA Status and Depression Severity in Relation to Memory
The MANCOVA results for the short-term memory VLMT parameters resulted in a significant
main effect for EPA status (F(10,194) = 2.094, p = 0.027) but not for depression severity (F(5,96) = 0.622,
p = 0.684). The between-subjects effects of EPA status were significant for the second trial (T2)
(F(2,100) = 6.096, p = 0.003) and reached borderline significance for T3 (F(2,100) = 4.825, p = 0.010) after
Bonferroni correction of the significance level (p < 0.01). Pairwise comparisons showed that patients
with a high EPA status (M = 10.96, SE = 0.37) outperformed patients with a moderate (M = 9.42,
SE = 0.35, p = 0.009) or low (M = 9.32, SE = 0.40, p = 0.010) EPA status in T2. The same results presented
for T3, where patients with a high EPA status (M = 12.23, SE = 0.35) outperformed patients with
a moderate (M = 10.97, SE = 0.33, p = 0.027) or low (M = 10.86, SE = 0.37, p = 0.023) EPA status.
The VLMT short-term memory score profiles for the three EPA status groups are shown in Figure 1.
The results indicate that patients with a high EPA status had steeper learning curves compared to
those with a moderate or low EPA status. No main effect of either EPA status or depression severity
presented for interference, long-term memory parameters, and the parameters of the digit span test.
All results are summarized in Table 3. Independent samples Kruskal–Wall tests showed no effect of
EPA status for either the uncorrected (H(2) = 0.893, p = 0.640) or the corrected (H(2) = 2.239, p = 0.326)
recognition parameter; there was also no significant effect of depression severity (U = 1370.500, p = 0.901
U = 1274.000, p = 0.580). Further analyses concerning potential confounding group differences revealed
no significant IQ differences between the six EPA/severity groups.
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Figure 1. VLMT learning curve in relation to EPA status. N = 107. * p < 0.05, ** p < 0.01.
3.3. Main Analysis—DHA Status and Depression Severity in Relation to Memory
The same analyses were run using DHA instead of EPA status as a factor. A significant interaction
effect for long-term memory parameters was found (F(4,200) = 3.069, p = 0.018). However, in contrast
to the EPA analyses where no IQ differences were found between the groups, further analyses revealed
significant IQ differences between moderately and severely depressed patients in the moderate DHA
status group. Moderately depressed patients had significantly higher GIX scores (M = 106.05, SD = 8.56)
compared to severely depressed patients in the moderate DHA status group (M = 97.62, SD = 10.57;
t(31) = 2.537, p = 0.016). Hence, the MANCOVA and ANCOVA analyses were rerun entering IQ as
a second covariate. A significant main effect for DHA status was found for digits forward scores
(F(2,91) = 3.342, p = 0.040). However, pairwise comparisons were no longer significant after Bonferroni
correction for multiple comparisons. No significant main effect for depression severity presented
for any memory parameter. A borderline significant interaction effect presented for interference
parameters of the VLMT (F(6,182) = 2.219, p = 0.052). Between-subjects effects revealed a significant
effect for the T6 parameter (F(2,92) = 4.337, p = 0.016) where severely depressed patients with a high
DHA status (M = 12.56, SE = 0.50) outperformed severely depressed patients with a moderate DHA
status (M = 10.50, SE = 0.61, p = 0.036). Moreover, in the moderate DHA status group, moderately
depressed patients (M = 12.34, SE 0.47) outperformed severely depressed patients (M = 10.50, SE = 0.61,
p = 0.021). IQ proved a significant covariate for nearly all parameters. All MANCOVA and ANCOVA
results are summarized in Table 4. Independent samples Kruskal–Wallis tests showed no effect of
DHA status for either the uncorrected (H(2) = 0.522, p = 0.770) or the corrected (H(2) = 2.054, p = 0.358)
recognition parameter.
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Table 3. Multivariate analysis of covariance (MANCOVA) and univariate analysis of covariance (ANCOVA) results for Verbaler Lern- und Merkfähigkeitstest (VLMT)








EPA: F(10,194) = 2.094, p = 0.027 *, ηp
2 = 0.097
S: F(5,96) = 0.622, p = 0.684, ηp2 = 0.031
I: F(10,194) = 0.910, p = 0.525, ηp2 = 0.045











EPA S I G
T1 score
Low EPA 6.52 (0.33) 6.55 (0.53) 1.044 0.816 0.415 0.6
NS NSModerate EPA 7.00 (0.35) 6.29 (0.46) 0.356 9.369 0.661 0.44
High EPA 7.11 (0.40) 7.06 (0.42) 0.02 0.008 0.008 0.006
T2 score
Low EPA 9.74 (0.52) 8.91 (0.69) 6.096 1.577 2.03 0
EPA: h >m
EPA: h > l
p = 0.009 **
p = 0.010 *
Moderate EPA 10.14 (0.56) 8.71 (0.46) 0.003 * 0.212 0.137 0.997
High EPA 10.67 (0.26) 11.25 (0.44) 0.109 0.016 0.039 0
T3 score
Low EPA 11.43 (0.40) 10.36 (0.64) 4.825 1.674 1.366 2.47
EPA: h >m
EPA: h > l
p = 0.027 *
p = 0.023 *
Moderate EPA 11.27 (0.52) 10.71 (0.45) 0.010 ◦ 0.199 0.26 0.119
High EPA 11.94 (0.38) 12.50 (0.52) 0.088 0.016 0.027 0.024
T4 score
Low EPA 12.17 (0.38) 10.91 (0.64) 2.652 0.944 0.082 3.069
NS NSModerate EPA 12.32 (0.50) 11.88 (0.70) 0.075 0.334 0.921 0.083
High EPA 13.00 (0.33) 13.06 (0.42) 0.05 0.009 0.002 0.03









EPA: F(10,194) = 2.094, p = 0.027 *, ηp
2 = 0.097
S: F(5,96) = 0.622, p = 0.684, ηp2 = 0.031
I: F(10,194) = 0.910, p = 0.525, ηp2 = 0.045











EPA S I G
T5 score
Low EPA 12.57 (0.38) 12.55 (0.51) 0.41 0.103 0.059 2.101
NS NSModerate EPA 12.32 (0.50) 12.18 (0.58) 0.665 0.749 0.942 0.15
High EPA 12.50 (0.41) 12.75 (0.37) 0.008 0.001 0.001 0.021
VLMT interference
parameters
EPA: F(6,198) = 1.426, p = 0.206, ηp2 = 0.041
S: F(3,98) = 1.056, p = 0.372, ηp2 = 0.031
I: F(6,198) = 0.102, p = 0.996, ηp2 = 0.003
G: F(3,98) = 0.869, p = 0.460, ηp2 = 0.026
I
Low EPA 6.43 (0.40) 6.18 (0.62) 1.671 2.28 0.079 1.414
NS NSModerate EPA 6.41 (0.44) 5.71 (0.58) 0.193 0.134 0.924 0.237
High EPA 7.33 (0.71) 6.63 (0.52) 0.032 0.022 0.002 0.014
T6
Low EPA 11.96 (0.59) 11.55 (0.56) 2.364 0.68 0.134 1.917
NS NSModerate EPA 11.36 (0.56) 10.94 (0.70) 0.101 0.411 0.875 0.169
High EPA 12.28 (0.43) 12.44 (0.48) 0.045 0.007 0.003 0.019
T5–6
Low EPA 0.61 (0.43) 1.00 (0.54) 2.556 0.756 0.075 0.107
NS NSModerate EPA 0.95 (0.24) 1.24 (0.36) 0.083 0.387 0.928 0.744
High EPA 0.22 (0.31) 0.31 (0.37) 0.049 0.008 0.001 0.001









EPA: F(4,200) = 0.604, p = 0.660, ηp2 = 0.012
S: F(2,99) = 0.055, p = 0.946, ηp2 = 0.001
I: F(4,200) = 0.093, p = 0.984, ηp2 = 0.002
G: F(2,99) = 1.123, p = 0.330, ηp2 = 0.022
T7
Low EPA 11.78 (0.54) 11.82 (0.48) 1.1 0.091 0.157 1.832
NS NSModerate EPA 11.55 (0.67) 11.18 (0.69) 0.337 0.763 0.855 0.179
High EPA 12.00 (0.46) 12.44 (0.58) 0.022 0.001 0.003 0.001
T5–7
Low EPA 0.78 (0.36) 0.73 (0.41) 0.774 0.007 0.123 0.128
NS NSModerate EPA 0.77 (0.44) 1.00 (0.39) 0.464 0.934 0.884 0.721








Low EPA 8.68 (0.44) 8.64 (0.41) 0.654 0.018 0.019 0.043
NS NSModerate EPA 8.45 (0.37) 8.29 (0.49) 0.522 0.894 0.981 0.837
High EPA 8.89 (0.40) 8.88 (0.52) 0.013 0 0 0
Digits backward
Low EPA 8.09 (0.41) 7.64 (0.49) 0.556 1.016 0.188 0.151
NS NSModerate EPA 8.41 (0.47) 7.88 (0.36) 0.575 0.316 0.829 0.699
High EPA 8.33 (0.43) 8.31 (0.27) 0.011 0.01 0.004 0.002
Note: ηp2 = 0.01 (small), 0.06 (medium), and 0.14 (large). l, low EPA; m, moderate EPA; h, high EPA. Group sizes (n): Moderately depressed with a low EPA status = 23; moderately
depressed with a moderate EPA status = 22; moderately depressed with a high EPA status = 18; severely depressed with a low EPA status = 11; severely depressed with a moderate EPA
status = 17; severely depressed with a high EPA status = 16. Multivariate effects, pairwise comparisons: ◦ borderline significant, * p < 0.05 ** p < 0.01. Between-subjects effects: ◦ borderline
significant, * p < 0.010 (short-term memory), * p < 0.017 (interference), and * p < 0.025 (long-term memory) after Bonferroni correction of the significance level. Significant effects are marked
in bold. T1–7, trials 1–7; NS, not significant.
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Interaction Severity * DHA Status (I)
Covariates: Gender (G), GIX (IQ)
VLMT short-term
memory parameters
DHA: F(10,178) = 1.323, p = 0.221, ηp2 = 0.069
S: F(5,88) = 0.524, p = 0.758, ηp2 = 0.029
I: F(10,178) = 0.686, p = 0.736, ηp2 = 0.037
G: F(5,88) = 1.218, p = 0.308, ηp2 = 0.065












DHA S I G IQ
T1 score
Low DHA 6.65 (1.61) 6.40 (2.07) 1.57 0.057 0.115 0.073 7.401
NS NSModerate DHA 7.25 (1.68) 7.00 (1.41) 0.214 0.812 0.892 0.788 0.008 *
High DHA 6.94 (1.61) 6.78 (1.90) 0.033 0.001 0.002 0.001 0.074
T2 score
Low DHA 9.87 (2.97) 8.91 (0.69) 1.733 0.923 0.323 0 14.652
NS NSModerate DHA 10.85 (2.87) 9.10 (2.13) 0.182 0.339 0.725 0.982 <0.001 *
High DHA 10.25 (1.18) 10.28 (2.63) 0.036 0.01 0.007 0 0.137
T3 score
Low DHA 11.09 (2.17) 11.50 (2.72) 1.096 0.184 0.641 3.039 15.105
NS NSModerate DHA 11.70 (2.06) 10.38 (2.06) 0.338 0.669 0.529 0.085 <0.001 *
High DHA 11.75 (2.05) 11.94 (1.86) 0.023 0.002 0.014 0.032 0.141
T4 score
Low DHA 11.96 (2.35) 12.20 (2.20) 1.769 0.1 0.913 2.062 31.252
NS NSModerate DHA 13.15 (1.73) 11.54 (3.05) 0.176 0.752 0.405 0.154 <0.001 *
High DHA 12.63 (1.09) 13.06 (1.51) 0.037 0.001 0.019 0.022 0.254





Interaction Severity * DHA Status (I)
Covariates: Gender (G), GIX (IQ)
VLMT short-term
memory parameters
DHA: F(10,178) = 1.323, p = 0.221, ηp2 = 0.069
S: F(5,88) = 0.524, p = 0.758, ηp2 = 0.029
I: F(10,178) = 0.686, p = 0.736, ηp2 = 0.037
G: F(5,88) = 1.218, p = 0.308, ηp2 = 0.065












DHA S I G IQ
T5 score
Low DHA 12.09 (2.28) 13.10 (1.60) 0.038 0.366 1.816 0.881 19.51
NS NSModerate DHA 13.05 (1.79) 11.77 (1.88) 0.963 0.547 0.169 0.35 <0.001 *
High DHA 12.44 (1.63) 12.89 (1.64) 0.001 0.004 0.038 0.009 0.175
VLMT interference
parameters
DHA: F(6,182) = 0.933, p = 0.472, ηp2 = 0.039
S: F(3,90) = 0.716, p = 0.545, ηp2 = 0.023
I: F(6,182) = 2.219, p = 0.052 ◦, ηp
2 = 0.066
G: F(3,90) = 0.480, p = 0.697, ηp2 = 0.016
IQ: F(3,90) = 8.593, p = < 0.001 ***, ηp
2 = 0.223
I
Low DHA 7.13 (2.70) 5.90 (2.38) 0.066 0.804 0.753 1.131 16.398
NS NSModerate DHA 6.60 (1.76) 5.92 (2.63) 0.936 0.372 0.474 0.29 <0.001 *
High DHA 6.25 (2.46) 6.39 (1.91) 0.001 0.009 0.016 0.012 0.151





Interaction Severity * DHA Status (I)
Covariates: Gender (G), GIX (IQ)
T6
Low DHA 11.43 (2.76) 12.70 (2.36) 1.405 0.006 4.337 0.445 12.435
I: s/h > s/m
I: m/m > s/m
p = 0.036 *
p = 0.021 *
Moderate DHA 12.45 (2.21) 10.00 (2.35) 0.251 0.936 0.016 * 0.506 0.001 *
High DHA 12.06 (1.95) 12.61 (1.29) 0.03 0 0.086 0.005 0.119
T5–6
Low DHA 0.65 (1.56) 0.40 (1.58) 2.621 0.613 1.959 0.017 0.006
NS NSModerate DHA 0.60 (1.60) 1.77 (1.64) 0.078 0.436 0.147 0.897 0.936
High DHA 0.38 (1.41) 0.28 (1.32) 0.054 0.007 0.041 0 0
VLMT Long-term
memory parameters
DHA: F(4,184) = 0.599, p = 0.664, ηp2 = 0.013
S: F(2,91) = 0.181, p = 0.835, ηp2 = 0.004
I: F(4,184) = 1.805, p = 0.130, ηp2 = 0.038
G: F(2,91) = 0.488, p = 0.615, ηp2 = 0.011
IQ: F(2,91) = 11.721, p < 0.001 ***, ηp
2 = 0.205
T7
Low DHA 11.70 (2.79) 11.90 (2.51) 0.804 0.151 1.598 0.744 19.794
NS NSModerate DHA 12.25 (2.95) 10.62 (2.18) 0.45 0.698 0.208 0.391 <0.001 *
High DHA 11.69 (2.02) 13.00 (1.33) 0.017 0.002 0.034 0.008 0.177
T5–7
Low DHA 0.39 (1.64) 1.20 (1.75) 1.11 0.011 1.86 0.031 1.802
NS NSModerate DHA 0.80 (2.12) 1.15 (1.46) 0.334 0.916 0.161 0.86 0.183
High DHA 0.75 (1.44) −0.11 (1.41) 0.024 0 0.039 0 0.019





Interaction Severity * DHA Status (I)




DHA: F(4,184) = 0.599, p = 0.664, ηp2 = 0.013
S: F(2,91) = 0.181, p = 0.835, ηp2 = 0.004
I: F(4,184) = 1.805, p = 0.130, ηp2 = 0.038
G: F(2,91) = 0.488, p = 0.615, ηp2 = 0.011









Low DHA 9.09 (2.18) 9.90 (1.37) 3.342 0.956 1.523 0.23 25.145
NS NSModerate DHA 8.45 (1.50) 7.85 (1.41) 0.040 * 0.543 0.224 0.633 <0.001 *
High DHA 8.69 (1.66) 8.28 (2.08) 0.068 0.004 0.032 0.003 0.216
Digits backward
Low DHA 8.64 (2.36) 8.60 (1.17) 0.78 0.005 0.192 0.058 17.851
NS NSModerate DHA 8.15 (1.81) 7.62 (1.26) 0.461 0.942 0.826 0.81 <0.001 *
High DHA 8.19 (1.64) 7.89 (1.61) 0.017 0 0.004 0.001 0.164
Note: GIX, global intelligence index. ηp2 = 0.01 (small), 0.06 (medium), and 0.14 (large). L, low DHA status; m, moderate DHA status; h, high DHA status; m/l, moderately depressed with
a low DHA status; m/m, moderately depressed with a moderate DHA status; m/h, moderately depressed with a high DHA status; s/l, severely depressed with a low DHA status; s/m,
severely depressed with a moderate DHA status; s/h, severely depressed with a high DHA status. Group sizes (n): m/l = 23; m/m = 20; m/h = 16; s/l = 10; s/m = 13; s/h = 18. Multivariate
effects, pairwise comparisons: ◦ borderline significant * p < 0.05, *** p < 0.001. Between-subjects effects: ◦ borderline significant, * p < 0.010 (short-term memory), * p < 0.017 (interference),
and * p < 0.025 (long-term memory) after Bonferroni correction of the significance level. Significant effects are marked in bold. T1–7, trials 1–7; NS, not significant.
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4. Discussion
The current study investigated RBC EPA and DHA levels, as well as depression severity in relation
to memory performance in a sample of 107 moderately to severely depressed youths.
Contrary to previous findings that reported inverse associations between oily fish intake and
depression severity [97], in our sample severely depressed patients had significantly higher DHA and
total omega-3 statuses compared to moderately depressed patients. Whereas negative associations
between EPA status and depression severity have been reported [49], we found no significant differences
concerning EPA status between moderately and depressed patients.
In our study, we examined potential cognitive deficits in depressed children and adolescents that
have been inconsistently found in previous studies [29–33] in contrast to research conducted in adult
patient groups, where deficits seem more consistent [19–25]. Although most patients achieved average
normative scores for both the VLMT and the digit span test, over 20% of the patients (compared to
an expected 15.9% in a healthy population) achieved below average normative scores. These results
indicate a tendency toward impaired verbal memory in depressed youths.
We further aimed at investigating potential negative associations between depression severity
and cognitive functioning in depressed youths that so far have mostly been reported in adult patient
groups [34,98], with similar tendencies from research conducted in children and adolescents [35].
Contrary to our hypothesis, in our sample we did not find any significant differences in verbal memory
performance between moderately and severely depressed patients. Hence, we could not confirm any
negative associations between depression severity and cognitive functions previously reported in adult
patient groups [34,98].
Most importantly, we were interested in memory performance in relation to EPA and DHA
status, because EPA supplementation has mostly been associated with beneficial cognitive effects in
youths [68,76], and beneficial cognitive effects would prove especially important in this vulnerable
population. Our results indicated that patients with a high EPA status had steeper learning curves
across the short-term memory trials of a verbal list learning test, compared to patients with a moderate
or low EPA status. Compared to patients with a moderate or low EPA status, those with a high
EPA status, seemed to remember more words faster, although they achieved equal scores in the first
trial and again in the last two trials. This finding only partly confirmed our hypothesis that patients
with a high EPA status would outperform patients with a low EPA status in verbal memory tests,
because differences were only observed for the second and third trials and not overall. Moreover,
these differences were only found for short-term memory parameters, whereas no significant effect
for EPA status presented for any other VLMT parameter or the digit span test. However, we were
able to confirm our hypothesis concerning DHA by finding no significant effect of DHA on any
verbal memory parameter. Both results are in line with previous findings from meta-analyses on
supplementation effects of EPA and DHA that suggested beneficial effects of EPA but not DHA on
cognitive functioning [68,76] and effects in clinical rather than healthy populations [68]. In contrast
to our hypothesis, we were not able to confirm any superior effects of a high EPA status in severely
compared to moderately depressed patients.
A number of limitations should be kept in mind when interpreting the reported results. First, no
healthy control group was investigated; hence, no comparison between depressed and healthy children
and adolescents could be made. Nevertheless, our data suggested that a somewhat larger proportion
of participants than expected in a healthy population achieved below average normative scores in
both tests. Importantly, the current study was based on a cross-sectional design. It is hence limited
by the impossibility to draw conclusions about any causal relationships. Another methodological
limitation lies in the small and unequally sized subgroups formed by the two factors of depression
severity and DHA and EPA status. Moreover, for several analyses the Levene’s tests proved significant.
However, rather conservative statistical methods for correction were applied throughout the analyses,
minimizing the probability of a type-I error.
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Our results further contribute to previous findings that reported some impairment considering
cognitive functions [29–31] and especially memory performance [33] in depressed youths. Future
studies should investigate differences between healthy and depressed individuals concerning memory
performance in order to be able to further confirm these findings and make recommendations for
cognitive assessments in this population. Surprisingly, the analyses of our sample revealed higher DHA
and total omega-3 status in severely compared to moderately depressed patients. One explanation for
this finding might lie in altered nutritional patterns in severely compared to moderately depressed
youths. Moreover, considering the population investigated, low n-3 PUFA levels were expected to
begin with, and hence, small ranges were presented. Wider ranges might therefore have produced
different results. This explanation is, of course, only speculative. Although the reported analyses with
EPA and DHA only contributed associations between RBC levels and verbal memory rather than effects
of supplementation, they further corroborate evidence from meta-analyses that confirmed the beneficial
supplementation effects of EPA but not DHA. Thus, our findings suggest that an increased dietary intake
of EPA might prove beneficial for cognitive improvement or even remission in depressed youths. Based
on our findings, future RCTs should investigate the effects of EPA compared to DHA supplementation
in depressed children and adolescents to potentially establish a recommendation for a natural and easily
accessible intervention for cognitive improvement or remission in depressed youths. Neuroimaging
studies have tried to explain differences in supplementation effectivity between DHA and EPA. Bauer
et al. [99], for example, reported a reduction in functional activation in the left anterior cingulate
cortex and shorter reaction times in the Stroop color–word task following EPA rather than DHA
supplementation, which, they argued, might represent stronger neural efficiency in EPA-supplemented
compared to DHA-supplemented individuals. Biologically, however, the supplementation advantages
of EPA over DHA have yet to be explained, considering EPA is found in much smaller concentrations
within the brain compared to DHA [60,100]. As there is also a lack of understanding about the actual
absorption and utilization of both EPA and DHA, it would be paramount to investigate the moderating
effects of, for example, the microbiome, as differences might be expected, and these again might explain
differential effects in different populations.
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